Certain types of university intellectual property can sometimes prove difficult to commercialise through traditional routes, usually because it is at an early stage of development, or because it presents enough uncertainty for companies to risk an investment.
University Technology’s Easy Access portal offers access to this type of intellectual property at no cost, to enable companies to evaluate it and put it to use quickly, with reduced risk.
Easy Access uses quick and simple licence agreements to fast-track the transfer of knowledge and expertise from Scotland’s universities to industry, so that these technologies may be developed for the benefit of the economy and society.
Through this initiative, our aim is to make it easier for Scottish universities and industry to work together and build strong, long-term relationships with industry partners.
Showing 1 - 10 of 11 opportunities
A novel therapeutic target for sickle cell disease and other haemolytic anaemias
The neurodegenerative inherited disease Spinal Muscular Atrophy (SMA) is the leading genetic cause of infant mortality, affecting 1:6,000 live births. SMA causes a loss of spinal motor neurons and is characterised by progressive muscular atrophy.
A tetrazine small-molecule trigger for activating prodrugs has been developed. Active molecules, such as a therapeutic drug or imaging fluorophore, can be caged within a polymer nanoparticle for controlled release at a targeted site.
A novel approach shows promising results as a potential therapeutic for allergic conditions, including severe steroid resistant asthma. A peptide has been identified, HpARI, that inactivates and inhibits release of IL-33 a critical step in the development of allergic disease.
These genetic markers have an identified association with the individual prediction of susceptibility and severity of Paget's disease of the bone.
These fully synthetic biocompatible polymers support effective human endothelial cell growth and endothelialisation, whilst minimising platelet attachment. The polymer materials can be applied as a thin coating to intra‐vascular devices and have the potential to minimise problems associated with vas...
This new approach converts chemotherapy agents into prodrugs, significantly reducing systemic toxicity, and enabling local activation only at tumour sites where a specific catalyst, palladium, has been implanted.
Researchers at the University of Dundee have designed and synthesised a novel, multifunctional protease inhibitor that has the potential to significantly enhance the performance of vaccines through proteolytic modulation.
A long non-coding RNA target that regulates the proliferation of vascular smooth muscle cells, is present in the plasma of cardiovascular disease patients, and found at increased levels in unstable regions of atherosclerotic plaques. Therapeutic targeting of this molecule could inhibit vascular remo...
The University of Glasgow has developed a (Ad-hTR-NTR) which has been extensively tested on Ovarian cancer cells.
Please select the market sector you are interested in.
Please select the university you are interested in.
Show only Easy Access opportunities.
Narrow your search with a few keywords.
Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities